SCHEMBL6327790

SCHEMBL6327790

C/N=C1/SCCN1Cc1ccc(Cl)nc1

nearest known ligand 0.71

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 3/20 0.71
MEN1 O00255 2/20 0.71
KMT2A Q03164 2/20 0.71
TDP1 Q9NUW8 1/20 0.71
CHRNA1 P02708 2/20 0.65
CHRNB2 P17787 1/20 0.49
CHRNA3 P32297 1/20 0.49
CHRNA4 P43681 1/20 0.49
ALDH1A1 P00352 2/20 0.44
ATM Q13315 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6327793 1.00 CHRNA7 (0.71) CHRNA7MEN1KMT2ATDP1CHRNA1
SCHEMBL9889726 1.00 CHRNA7 (0.71) CHRNA7MEN1KMT2ATDP1CHRNA1
SCHEMBL14606326 0.88 CHRNA7 (0.73) CHRNA7MEN1KMT2ATDP1CHRNA1
SCHEMBL6324205 0.86 CHRNA7 (0.71) CHRNA7MEN1KMT2ATDP1CHRNA1
SCHEMBL13283613 0.86 CHRNA7 (0.71) CHRNA7MEN1KMT2ATDP1CHRNA1
SCHEMBL13516536 0.86 CHRNA7 (0.71) CHRNA7MEN1KMT2ATDP1CHRNA1
SCHEMBL13516537 0.86 CHRNA7 (0.71) CHRNA7MEN1KMT2ATDP1CHRNA1
SCHEMBL6324210 0.86 CHRNA7 (0.71) CHRNA7MEN1KMT2ATDP1CHRNA1
SCHEMBL6325078 0.84 CHRNA7 (0.68) CHRNA7MEN1KMT2ATDP1CHRNA1
SCHEMBL6325074 0.84 CHRNA7 (0.68) CHRNA7MEN1KMT2ATDP1CHRNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030078259-A1 Di-substituted imineheterocyclic compounds DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-04-24 US claimed
EP-1218371-A2 DI-SUBSTITUTED IMINOHETEROCYCLIC COMPOUNDS SUNTORY LIMITED (JP) 2002-07-03 EP claimed
WO-2001070733-A2 DI-SUBSTITUTED IMINOHETEROCYCLIC COMPOUNDS SUNTORY LIMITED (JP) 2001-09-27 WO claimed
US-6900202-B2 Di-substituted imineheterocyclic compounds DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2005-05-31 US disclosed
US-20030078259-A1 Di-substituted imineheterocyclic compounds DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-04-24 US disclosed
EP-1218371-A2 DI-SUBSTITUTED IMINOHETEROCYCLIC COMPOUNDS SUNTORY LIMITED (JP) 2002-07-03 EP disclosed
WO-2001070733-A2 DI-SUBSTITUTED IMINOHETEROCYCLIC COMPOUNDS SUNTORY LIMITED (JP) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078259-A1 Di-substituted imineheterocyclic compounds CHRNA2, CHRNA7, CHRNB2 CHRNA7 2/4885MEN1 2653/4885KMT2A 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.